Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Sep
12
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo